Get the Stockscreener App
234.76
2.07%
4.75
Pre-market:
235.46
0.70
+0.30%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $234.76, with a volume of 7.19M.
It is up +2.07% in the last 24 hours and up +8.84% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$230.01
Open:
$232.97
24h Volume:
7.19M
Relative Volume:
1.11
Market Cap:
$414.77B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
115.79
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+5.52%
1M Performance:
+8.84%
6M Performance:
+2.61%
1Y Performance:
+27.75%
1-Day Range:
$231.30
$235.31
1-Week Range:
$215.37
$235.31
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
234.76 | 414.77B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,107.08 | 987.23B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
239.08 | 575.52B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
119.60 | 295.39B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.38 | 292.66B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com Canada
PRESCRIPTION DRUGS—W.D. Wash.: Novartis, AbbVie, PhRMA denied preliminary relief in challenge to Washington State 340B delivery law - VitalLaw.com
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors. - Yahoo Finance
Here's How Much You'd Need to Invest in HDV to Generate $500 per Month in Dividends - The Motley Fool
ABBV Reiterated by Piper Sandler -- Price Target Maintained at $298 - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds - PR Newswire
CCORF Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $273 - Moomoo
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout - Yahoo Finance
Abbvie stock holds at Market Perform as Bernstein eyes Apogee deal - Investing.com Canada
ABBV Introduces Boey for Glabellar Lines Following Health Canada Approval - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $234 to $298 - Moomoo
AbbVie receives European approval for age three patients - grafa.com
Years of Rewards: $61 Bil From AbbVie Stock - Trefis
Canaccord raises Abbvie stock price target on acquisition potential - Investing.com
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) - Yahoo Finance
Canaccord raises Abbvie stock price target on acquisition potential By Investing.com - Investing.com Canada
Should You Buy Or Sell AbbVie Stock At $230? - Yahoo Finance
Possible Bearish Signals With AbbVie Insiders Disposing Stock - Moomoo
AbbVie Stock Rose 6% After Its $11 Billion Apogee Deal: What a $347 Target Means for Investors - TIKR.com
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Canada clears Boey, a fast-acting neurotoxin that fades in 2-3 weeks - Stock Titan
AbbVie receives European approval for age six patients - grafa.com
AbbVie (ABBV) Gains European Approval for Skyrizi in Younger Pat - GuruFocus
ABBV Receives EU Approval for Maviret Treatment - GuruFocus
AbbVie (ABBV) Secures EU Approval for Skyrizi in Pediatric Psori - GuruFocus
AbbVie (ABBV) Gains European Approval for SKYRIZI in Pediatric P - GuruFocus
AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection - Investing News Network
AbbVie Inc. (ABBV) Apogee Therapeutics, Inc.M&A CallSlideshow (NYSE:ABBV) 2026-06-23 - Seeking Alpha
AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis - Investing News Network
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection - Yahoo Finance
UBS downgrades Apogee Therapeutics stock rating on AbbVie deal - Investing.com
Key facts: AbbVie to Buy Apogee for $10.9B; Lead Drug Ph3 Expected - TradingView
AbbVie’s SKYRIZI cleared for kids with plaque psoriasis in Europe - Stock Titan
AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge - MedCity News
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition - Insider Monkey
Why AbbVie Stock Jumped Today - The Motley Fool
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - Investing News Network
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger - Insider Monkey
Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee - NAI500
AbbVie: Apogee Acquisition Brings Significant Weight to Immunology Pipeline - Morningstar
AbbVie's Immunology Dominance Contributes to Its Wide Economic Moat - Morningstar
AbbVie M&A, FDA reversals, a CAR T first — a BioCentury podcast - BioCentury
AbbVie seeks further extension to immunology franchise via $10.9B Apogee deal - BioCentury
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? - Yahoo Finance
ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032 - TradingView
Parkinson’s Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail - Barchart.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):